Innovate

Identification and control of impurities in active pharmaceutical ingredients (APIs) and pharmaceutical drug products is critical in drug development. Mirabilis is our innovative solution designed to address this challenge. In this post, we’ll answer ten frequently asked questions about Mirabilis.   What is Mirabilis? Mirabilis is an in silico tool developed by Lhasa Limited that […]

For over four decades, at Lhasa Limited we have been developing scientific software solutions that enable scientists to make informed decisions on the safety of drugs, chemicals and cosmetics. Our journey advanced significantly with the creation of Derek Nexus, an in silico expert knowledge-based toxicity prediction tool. As regulatory landscapes evolved and the push for

Explore key insights from the Lhasa Limited and IPEC Europe Nitrites meeting, where attendees discussed advancing nitrosamine understanding.   “The meeting provided an opportunity to share our common difficulties and discuss solutions to establish robust and accurate methods for analysing nitrites in excipients.” We recently welcomed members of the Lhasa Nitrites data sharing consortium and

Cannabidiol (CBD) is gaining prominence as a sought-after ingredient in skincare and beauty formulations, thanks to its notable anti-inflammatory, antioxidant and anti-bacterial properties. Derived directly from the hemp plant, this compound is increasingly being used as an ingredient in skincare products, particularly for the management of various skin conditions like eczema, dermatitis and psoriasis. Despite

Following the success of the 2022 Science of Stability (SOS) Conference in Philadelphia, we’re excited to announce its return to Barcelona! The 8th SOS will take place on the 13-14th May 2024, and we’re delighted to co-host it with FreeThink Technologies. With a focus on innovation and collaboration, this promises to be a milestone event

We are delighted to share our important new open access article: In silico prediction of pharmaceutical degradation pathways: A benchmarking study using the software program Zeneth. The paper, recently published in Organic Process Research & Development (OPRD) is authored by Lhasa Principal Scientist Rachel Hemingway, alongside industry expert co-authors from AstraZeneca, GSK, Pfizer, BMS, Amgen

At Lhasa, we believe in the transformative power of knowledge sharing as the driving force to support the global challenge of nitrosamine risk assessment. Through data sharing and industry collaboration, we empower members to further understand the risks associated with their potential nitrosamine impurities. The Vitic Complex Nitrosamines initiative, launched in 2021 in response to